The University of Chicago Header Logo

Connection

Peter H. O'Donnell to Pharmacogenetics

Back to Details
This is a "connection" page, showing publications Peter H. O'Donnell has written about Pharmacogenetics.
Peter H. O'Donnell
Connection Strength
12.895
Pharmacogenetics
  1. Modern developments in germline pharmacogenomics for oncology prescribing. CA Cancer J Clin. 2022 07; 72(4):315-332.
    View in: PubMed
    Score: 0.632
  2. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.
    View in: PubMed
    Score: 0.630
  3. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
    View in: PubMed
    Score: 0.606
  4. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200.
    View in: PubMed
    Score: 0.578
  5. Incorporating preemptive pharmacogenomic testing into the clinical setting. Clin Adv Hematol Oncol. 2020 09; 18(9):526-529.
    View in: PubMed
    Score: 0.568
  6. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
    View in: PubMed
    Score: 0.558
  7. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135.
    View in: PubMed
    Score: 0.531
  8. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537.
    View in: PubMed
    Score: 0.510
  9. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38.
    View in: PubMed
    Score: 0.509
  10. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30.
    View in: PubMed
    Score: 0.509
  11. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.484
  12. Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. J Biomed Inform. 2017 Nov; 75:110-121.
    View in: PubMed
    Score: 0.464
  13. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869.
    View in: PubMed
    Score: 0.455
  14. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114.
    View in: PubMed
    Score: 0.449
  15. Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90.
    View in: PubMed
    Score: 0.424
  16. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4.
    View in: PubMed
    Score: 0.415
  17. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29.
    View in: PubMed
    Score: 0.395
  18. Pharmacogenomics and cardiology: improving treatment with existing drugs. Pharmacogenomics. 2015; 16(11):1223-6.
    View in: PubMed
    Score: 0.384
  19. Unleashing the power of preemptive pharmacogenomics. Clin Adv Hematol Oncol. 2014 Oct; 12(10):695-7.
    View in: PubMed
    Score: 0.377
  20. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75.
    View in: PubMed
    Score: 0.363
  21. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012 Oct; 92(4):446-9.
    View in: PubMed
    Score: 0.326
  22. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
    View in: PubMed
    Score: 0.316
  23. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9.
    View in: PubMed
    Score: 0.313
  24. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics. 2010 May; 20(5):327-37.
    View in: PubMed
    Score: 0.278
  25. Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2024 Mar; 61(2):89-106.
    View in: PubMed
    Score: 0.176
  26. Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
    View in: PubMed
    Score: 0.166
  27. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86.
    View in: PubMed
    Score: 0.159
  28. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
    View in: PubMed
    Score: 0.157
  29. Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
    View in: PubMed
    Score: 0.154
  30. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052.
    View in: PubMed
    Score: 0.153
  31. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393.
    View in: PubMed
    Score: 0.146
  32. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
    View in: PubMed
    Score: 0.132
  33. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827.
    View in: PubMed
    Score: 0.131
  34. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510.
    View in: PubMed
    Score: 0.114
  35. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7.
    View in: PubMed
    Score: 0.087
  36. Bladder cancer pharmacogenomics: recent insights and future perspectives. Pharmacogenomics. 2012 Nov; 13(14):1553-6.
    View in: PubMed
    Score: 0.083
  37. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12.
    View in: PubMed
    Score: 0.068
  38. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14.
    View in: PubMed
    Score: 0.066
  39. The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. Clin Transl Sci. 2019 05; 12(3):209-217.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.